James M. Daly - Jun 7, 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Jun 7, 2022
Transactions value $
$0
Form type
4
Date filed
6/9/2022, 08:30 PM
Previous filing
May 6, 2022
Next filing
Jun 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Director Stock Options (Right to Buy) Award $0 +14.4K $0.00 14.4K Jun 7, 2022 Common Stock 14.4K $18.27 Direct F1
transaction ACAD Restricted Stock Units Award $0 +8.55K $0.00 8.55K Jun 7, 2022 Common Stock 8.55K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest quarterly over one year following the date of grant, with the final tranche vesting upon the earlier of one year following the date of grant or the next annual meeting date.
F2 Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
F3 The restricted stock units shall vest in full upon the earlier of one year following the date of grant or the next annual meeting date.